At J.M. Kyriakidis SA we serve public health. Our purpose is to help organizations and healthcare professionals provide the highest quality health services.

+30 210 6072700
info@jmkyriakidis.gr
Garittou & Acherontos 1, 15343 Agia Paraskevi

Agia Paraskevi 15343
+30 210-6072700
Working Hours Monday-Friday 08:30-16:30
Image Alt

Προϊόντα

LUMIPULSE® G600II

LUMIPULSE G600II benchtop analyzer

 

SKU: fujirebio-g600
Categories: , ,

Description

LUMIPULSE® G600II

Lumipulse G CLIA analyzer cartridge close up

Simplify your laboratory workflow using the LUMIPULSE G600II benchtop analyzer as a personalized solution!

The LUMIPULSE G600II is the latest member of the LUMIPULSE G series, the chemiluminescent enzyme immunoassay (CLEIA) analyzers from Fujirebio. It is a compact and robust benchtop analyzer featuring a constant throughput of 60 tests per hour.

The system uses a unique mono test cartridge concept (the same cartridge concept as the mid-sized LUMIPULSE G1200 analyzer) and offers outstanding flexibility and easy handling to hospitals and clinical laboratories. The easy-to-use benchtop analyzer provides a perfect fit in laboratories aiming for personalized workflow solutions without compromising testing quality.

CE marked

Test Menu

https://www.fujirebio.com/en/products-solutions/kits-for-fully-automated-testing

Specifications

  1. Runs 60 tests per hour, giving results in just 35 minutes
  2. The reagents are in mono test format, ready to use
  3. Random Access and continuous loading
  4. Long calibration stability
  5. Single-use tips to minimize any risks of contamination
  6. Long on-board reagent stability
  7. Bi-directional connection to LIS.

Neurodegeneratiion Menu

Pioneers in early and reliable Alzheimer’s disease diagnostics

Cerebrospinal fluid (CSF) biomarkers, developed first by Fujirebio more than 25 years ago, have evolved over time from research biomarkers to specialized diagnostic testing, and from usage by early adopters to a widespread implementation as routine testing today.

Diagnosis based on CSF samples allows the detection of four proteins; two forms of amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and phospho-Tau) proteins. If a patient has Alzheimer’s disease, then these proteins will be present in abnormally low (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) and high (Total Tau and phospho-Tau) levels. The Aβ1-42 protein levels will even be low before the symptoms of the disease start to show.

COVID-19

For in vitro diagnostic (IVD) use with the Lumipulse G system for detection and quantitative measurement of SARS-CoV-2 nucleocapsid protein antigen in human nasopharyngeal swab or saliva. As a diagnostic tool for the confirmation of a SARS-CoV-2 infection.

The assay utilises proven CLEIA (chemiluminescent enzyme immunoassay) technology with results that are available in up to 35 minutes.

CE marked

Related products